Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Rise of Mid-Sized Pharma
2.
Contract Research Annual Review 2008
3.
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
4.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
5.
Monoclonal Antibodies Report: 2008 Update
6.
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players
7.
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
8.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
9.
Drug Repositioning Strategies - Serendipity by design
10.
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Immunogenicity to Biologics Implications of reactions against biotech drugs
3.
Outsourcing in Drug Discovery, 3rd Edition
4.
American Hospital Register
5.
Professional Designation in Biopharmaceutical Technology - 3 Course Curriculum
6.
Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
Ovarian Cancer Drug Pipeline Update 2008
With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication for existing and pipeline drugs.
There are today more than 200 therapeutics targeting ovarian cancer, from early preclinical to marketed drugs. Ovarian Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 119 different targets. These targets are further categorized on the CD-ROM by 42 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Ovarian Cancer Drug Pipeline Update is organized.
How May Drug Pipeline Update Be of Use?
* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
* Find competitors, collaborations partners, M&A candidates etc.
* Jump start competitive drug intelligence operations
* Excellent starting point for world wide benchmarking
* Compare portfolio and therapy focus with your peers
* Speed up pro-active in-/out licensing strategy work
* Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.
Drug Pipeline Update is delivered to you as a CD-ROM application, which requires no installation on your computer. Please read more about application features and system requirements - hit more..
May 2008
More...
Price: $2,650.00 / GBP1,325.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.